Aligos Therapeutics Q2 2024 GAAP EPS $0.03 Beats $(0.16) Estimate, Sales $1.061M Down From $2.592M YoY
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics (NASDAQ:ALGS) reported Q2 2024 GAAP EPS of $0.03, significantly beating the analyst estimate of $(0.16). However, sales dropped by 59.07% year-over-year to $1.061 million from $2.592 million.
August 06, 2024 | 9:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aligos Therapeutics reported a Q2 2024 GAAP EPS of $0.03, beating the analyst estimate of $(0.16) by 118.75%. However, sales decreased by 59.07% year-over-year to $1.061 million.
The significant EPS beat is likely to have a positive short-term impact on the stock price, despite the substantial year-over-year decline in sales. Investors may focus on the earnings beat as a sign of improved profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100